Loading clinical trials...
Loading clinical trials...
Exploratory Efficacy and Safety, Pharmacokinetics and Dose Finding Study of ATryn® (Antithrombin Alfa) in Patients With Disseminated Intravascular Coagulation Associated With Severe Sepsis
The primary objective of the study is to explore the efficacy and safety of ATryn® (antithrombin alfa) for the treatment of disseminated intravascular coagulation (DIC) associated with severe sepsis, when administered by continuous intravenous (IV) infusion over five days.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Start Date
July 1, 2007
Primary Completion Date
March 1, 2009
Completion Date
March 1, 2009
Last Updated
March 7, 2025
25
ACTUAL participants
Antithrombin alfa (INN name)
DRUG
Control (Standard treatment)
DRUG
Lead Sponsor
LEO Pharma
NCT07234630
NCT01704001
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00487656